Neoajuvant Tislelizumab Combined with Chemotherapy for Initially Unresectable Stage IIIA/N2 Non-small Cell Lung Cancer

NCT06614231 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

48

Enrollment

OTHER

Sponsor class

Conditions

NSCLC, Stage IIIA
NSCLC (non-small Cell Lung Cancer)

Interventions

DRUG: Tislelizumab Combined With Chemotherapy

Sponsor

Sun Yat-sen University